These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 35438767)

  • 1. Thyroid Hormone Abuse in Elite Sports: The Regulatory Challenge.
    Gild ML; Stuart M; Clifton-Bligh RJ; Kinahan A; Handelsman DJ
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3562-e3573. PubMed ID: 35438767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of the COVID-19 pandemic on the use of the performance-enhancing drugs.
    Negro F; Di Trana A; Marinelli S
    Acta Biomed; 2022 Jan; 92(6):e2021401. PubMed ID: 35075058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Australian athletes' knowledge of the WADA Prohibited Substances List and performance enhancing substances.
    Orr R; Grassmayr M; Macniven R; Grunseit A; Halaki M; Bauman A
    Int J Drug Policy; 2018 Jun; 56():40-45. PubMed ID: 29550541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyroid Hormone Abuse Among Elite Athletes.
    Handelsman DJ; Gild M; Clifton-Bligh R; Speers N; Kouzios D; McMartin MC; Desai R
    J Endocr Soc; 2023 Mar; 7(5):bvad027. PubMed ID: 36896254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone abuse in sports: the antidoping perspective.
    Barroso O; Mazzoni I; Rabin O
    Asian J Androl; 2008 May; 10(3):391-402. PubMed ID: 18385901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doping control from a global and national perspective.
    Fraser AD
    Ther Drug Monit; 2004 Apr; 26(2):171-4. PubMed ID: 15228160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Between medical treatment and performance enhancement: an investigation of how elite athletes experience Therapeutic Use Exemptions.
    Overbye M; Wagner U
    Int J Drug Policy; 2013 Nov; 24(6):579-88. PubMed ID: 23582632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating the elite athlete: anti-doping information for the health professional.
    Tandon S; Bowers LD; Fedoruk MN
    Mo Med; 2015; 112(2):122-8. PubMed ID: 25958657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doping and musculoskeletal system: short-term and long-lasting effects of doping agents.
    Nikolopoulos DD; Spiliopoulou C; Theocharis SE
    Fundam Clin Pharmacol; 2011 Oct; 25(5):535-63. PubMed ID: 21039821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Medication, athletes and doping regulations].
    Hartgens F
    Ned Tijdschr Geneeskd; 2008 Aug; 152(33):1844-8. PubMed ID: 18783164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of prohibited substances for therapeutic reasons in athletes affected by endocrine diseases and disorders: the therapeutic use exemption (TUE) in clinical endocrinology.
    Di Luigi L; Pigozzi F; Sgrò P; Frati L; Di Gianfrancesco A; Cappa M
    J Endocrinol Invest; 2020 May; 43(5):563-573. PubMed ID: 31734891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recreational and ergogenic substance use and substance use disorders in elite athletes: a narrative review.
    McDuff D; Stull T; Castaldelli-Maia JM; Hitchcock ME; Hainline B; Reardon CL
    Br J Sports Med; 2019 Jun; 53(12):754-760. PubMed ID: 31097457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An (un)desirable trade of harms? How elite athletes might react to medically supervised 'doping' and their considerations of side-effects in this situation.
    Overbye M
    Int J Drug Policy; 2018 May; 55():14-30. PubMed ID: 29477956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cannabis in sport: anti-doping perspective.
    Huestis MA; Mazzoni I; Rabin O
    Sports Med; 2011 Nov; 41(11):949-66. PubMed ID: 21985215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating the use of stimulants in out-of-competition sport samples.
    Boghosian T; Mazzoni I; Barroso O; Rabin O
    J Anal Toxicol; 2011 Nov; 35(9):613-6. PubMed ID: 22080900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Athletes and Supplements: Prevalence and Perspectives.
    Garthe I; Maughan RJ
    Int J Sport Nutr Exerc Metab; 2018 Mar; 28(2):126-138. PubMed ID: 29580114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of prohibited substances and methods in sports: Unveiling trends, pharmacokinetics, and WADA evolution.
    Oleksak P; Nepovimova E; Valko M; Alwasel S; Alomar S; Kuca K
    Environ Toxicol Pharmacol; 2024 Jun; 108():104447. PubMed ID: 38636744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidoping program: an important factor in the promotion and protection of the integrity of sport and athlete's health.
    Mazzeo F; Monda V; Santamaria S; Nigro E; Valenzano A; Villano I; Cibelli G; Messina A; Messina G
    J Sports Med Phys Fitness; 2018; 58(7-8):1135-1145. PubMed ID: 28738670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-doping Policy, Therapeutic Use Exemption and Medication Use in Athletes with Asthma: A Narrative Review and Critical Appraisal of Current Regulations.
    Allen H; Backhouse SH; Hull JH; Price OJ
    Sports Med; 2019 May; 49(5):659-668. PubMed ID: 30887312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The World Anti-Doping Code 2003--consequences for physicians associated with elite athletes.
    Striegel H; Rössner D; Simon P; Niess AM
    Int J Sports Med; 2005 Apr; 26(3):238-43. PubMed ID: 15776342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.